The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells
- PMID: 19360306
- DOI: 10.3892/or_00000353
The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells
Abstract
The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a successful TRAIL-based treatment regimen in the future. In this context, it would be a major advantage to be able to identify the tumours that respond to TRAIL. The existence of two apoptosis-inducing receptors (TRAIL-R1 and TRAIL-R2) and two receptors that cannot transmit an apoptotic signal and have an inhibitory function (TRAIL-R3 and TRAIL-R4) make TRAIL signalling complicated. We analysed the surface expression of all four membrane-bound TRAIL receptors in cancer cell lines of various origin and primary cancer and normal cells and found a good correlation between TRAIL-sensitivity and the expression of TRAIL-R1 alone, but an even better correlation when a ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4 was analysed. Experimental overexpression of TRAIL-R1 alone or in combination with TRAIL-R4 in PANC-1 cells confirmed our correlation results. Similar to the surface expression-apoptosis correlation analysis we found a high correlation between TRAIL-sensitivity and the mRNA level ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4. A value of <0.85 for the ratio predicted TRAIL resistance in both protein and RNA analysis. Hence, TRAIL receptor RNA expression analysis by real-time PCR might be a feasible approach to predict possible TRAIL-responses in individual tumour samples.
Similar articles
-
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.Leukemia. 2001 Jun;15(6):921-8. doi: 10.1038/sj.leu.2402131. Leukemia. 2001. PMID: 11417478
-
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.Cancer Res. 1999 Jun 1;59(11):2747-53. Cancer Res. 1999. PMID: 10364001
-
Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.J Immunol. 2000 Apr 15;164(8):3961-70. doi: 10.4049/jimmunol.164.8.3961. J Immunol. 2000. PMID: 10754286
-
TRAIL receptor signalling and modulation: Are we on the right TRAIL?Cancer Treat Rev. 2009 May;35(3):280-8. doi: 10.1016/j.ctrv.2008.11.006. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117685 Review.
-
TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.Int J Biochem Cell Biol. 2009 Mar;41(3):460-6. doi: 10.1016/j.biocel.2007.12.012. Epub 2007 Dec 28. Int J Biochem Cell Biol. 2009. PMID: 18243765 Review.
Cited by
-
MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells.Cancers (Basel). 2019 Apr 21;11(4):568. doi: 10.3390/cancers11040568. Cancers (Basel). 2019. PMID: 31010082 Free PMC article.
-
Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential.Cancer Sci. 2013 May;104(5):558-62. doi: 10.1111/cas.12112. Epub 2013 Feb 28. Cancer Sci. 2013. PMID: 23347256 Free PMC article.
-
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Eur J Pharmacol. 2009 Dec 25;625(1-3):63-72. doi: 10.1016/j.ejphar.2009.06.066. Epub 2009 Oct 18. Eur J Pharmacol. 2009. PMID: 19836385 Free PMC article. Review.
-
Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.Apoptosis. 2022 Dec;27(11-12):787-799. doi: 10.1007/s10495-022-01774-5. Epub 2022 Oct 7. Apoptosis. 2022. PMID: 36207556
-
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.Cell Death Dis. 2013 Feb 21;4(2):e503. doi: 10.1038/cddis.2013.19. Cell Death Dis. 2013. PMID: 23429289 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources